...
首页> 外文期刊>Cell death & disease. >A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma
【24h】

A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma

机译:A20靶向PFK1和糖酵解,以抑制肝细胞癌的进展

获取原文
           

摘要

Abnormal expression of the E3 ubiquitin ligase A20 has been found in some malignant cancers, including hepatocellular carcinoma (HCC). Here, we discovered that A20 is an E3 ubiquitin ligase for phosphofructokinase, liver type (PFKL) in HCC A20 interacts with PFKL and promotes its degradation, therefore inhibiting glycolysis in HCC cell lines. Downregulation of A20 in HCC cells promotes proliferation, migration, and glycolysis, all of which can be inhibited by targeting PFKL with RNA interference. Importantly, A20 is downregulated in advanced HCC tissues and inversely correlated with PFKL expression. Thus, our findings establish A20 as a critical regulator of glycolysis and reveal a novel mechanism for A20 in tumor suppression and PFKL regulation. Given that an increased level of glycolysis is linked with HCC, this study also identifies potential therapeutic targets for HCC treatment.
机译:在一些恶性癌症中发现了E3泛素连接酶A20的异常表达,包括肝细胞癌(HCC)。在这里,我们发现A20是磷蛋白酶酶的E3泛素连接酶,HCC A20中的肝型(PFK1)与PFK1相互作用并促进其降解,从而抑制HCC细胞系中的糖酵解。 HCC细胞中A20的下调促进了增殖,迁移和糖酵解,所有这些都可以通过靶向具有RNA干扰的PFK1来抑制。重要的是,A20在高级HCC组织中下调并与PFK1表达逆为相关。因此,我们的研究结果建立了A20作为糖酵解的临界调节剂,并揭示了A20中A20的一种新机制和PFKL调节。鉴于糖醇的水平增加与HCC有关,本研究还确定了HCC治疗的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号